View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Steatohepatitis/Metabolic Liver Disease News

SPONSORED CONTENT
November 20, 2024
2 min read
Save
GLP-1RAs confer ‘metabolic benefit,’ lower odds for MASLD after liver transplantation

GLP-1RAs confer ‘metabolic benefit,’ lower odds for MASLD after liver transplantation

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.

SPONSORED CONTENT
November 19, 2024
3 min read
Save

Monthly efimosfermin offers ‘rapid, meaningful’ improvement for MASH, related fibrosis

Monthly efimosfermin offers ‘rapid, meaningful’ improvement for MASH, related fibrosis

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.

SPONSORED CONTENT
November 18, 2024
2 min read
Save

Liver stiffness measurements may ‘personalize’ HCC risk, surveillance needs in MASLD

Liver stiffness measurements may ‘personalize’ HCC risk, surveillance needs in MASLD

SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
November 18, 2024
2 min read
Save

Novel farnesoid X receptor agonist safe, reduces liver fat content by up to 22.8% in MASH

Novel farnesoid X receptor agonist safe, reduces liver fat content by up to 22.8% in MASH

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting.

SPONSORED CONTENT
November 18, 2024
2 min read
Save

GLP-1RAs may offer ‘hepatoprotective’ benefit for diabetes, alcohol-related liver disease

GLP-1RAs may offer ‘hepatoprotective’ benefit for diabetes, alcohol-related liver disease

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.

SPONSORED CONTENT
November 13, 2024
4 min watch
Save

VIDEO: ‘What you can do now’ for patients with MASLD

VIDEO: ‘What you can do now’ for patients with MASLD

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, provides an overview of her postgraduate course presentation at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
November 11, 2024
1 min watch
Save

VIDEO: Better rates of fibrosis reversal in MASH with Rezdiffra 100 mg, data show

VIDEO: Better rates of fibrosis reversal in MASH with Rezdiffra 100 mg, data show

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
October 18, 2024
2 min read
Save

Denifanstat a ‘promising oral therapy’ for the treatment of MASH, related fibrosis

Denifanstat a ‘promising oral therapy’ for the treatment of MASH, related fibrosis

Patients treated with denifanstat 50 mg vs. placebo achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis, according to study results in The Lancet Gastroenterology & Hepatology.

SPONSORED CONTENT
October 17, 2024
2 min read
Save

Multiparametric MRI liver biomarkers predict those ‘likely to achieve’ MASH resolution

Multiparametric MRI liver biomarkers predict those ‘likely to achieve’ MASH resolution

Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.

SPONSORED CONTENT
October 10, 2024
2 min read
Save

Hispanic, Asian populations in US at highest risk for alcohol-associated liver disease

Hispanic, Asian populations in US at highest risk for alcohol-associated liver disease

Significant differences in alcohol use, alcohol-related mortality and liver transplant rate by race and ethnicity underscore the need for “tailored approaches to managing” alcohol-related liver disease in the U.S., according to a researcher.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails